Skip to Content
Event ANT Neuromeeting 2027 - Berlin starts on Jan 14, 2027, 8:00:00 AM (Europe/Berlin)
EEG Biomarkers, AI and Precision Psychiatry
Location: Lecture Hall - 1/14/27, 2:00 PM - 1/14/27, 2:30 PM (Europe/Berlin) (30 minutes)
EEG Biomarkers, AI and Precision Psychiatry
Prof. Dr. Sebastian Olbrich
Principal Investigator at Department for Psychiatry, University Zurich
Prof. Dr. Sebastian Olbrich
Principal Investigator at Department for Psychiatry, University Zurich
Biography: 
Sebastian Olbrich studied medicine in Munich, Germany, and completed specialized training in psychiatry at the University of Leipzig. Since 2014, he has been part of the University Hospital Zurich, where he now serves as the Chief of the Center for Depression, Anxiety Disorders, and Psychotherapy. His research focuses on identifying predictive biomarkers for treatment outcomes in psychiatric disorders, with a particular emphasis on depression. Dr. Sebastian Olbrich and his team are pioneers in using advanced deep learning techniques to analyze EEG and ECG time series data, striving to achieve the highest possible accuracy in their predictive models. He is also the co-founder of DeepPSY, a company that develops EEG/ECG-based medical reports for personalized treatment recommendations.

Talk Abstract: 
Can a few minutes of resting-state EEG help us choose the right treatment for depression? Despite expanding therapeutic options, treatment selection still relies largely on trial and error. EEG-based biomarkers and artificial intelligence offer an opportunity to make these decisions more informed—and more individual.

This talk traces the journey from biomarker discovery to clinical implementation. Drawing on our work with DeepPsy, it explores how EEG and ECG features can be translated into clinically accessible reports to support treatment stratification. Complementary deep-learning approaches investigate whether patterns in resting-state EEG can predict antidepressant response across independent datasets. Clinical implementation and real-world analyses provide insights into feasibility and potential utility, while highlighting the challenges of generalisability, validation and integration into everyday care.

The next step is PRECISE-MDD, a multicentre randomised controlled trial designed to test whether biomarker-guided treatment selection improves outcomes compared with standard care. Bringing together interpretable biomarkers, AI and prospective clinical validation, the talk addresses a central question: How do we turn promising predictions into better treatment decisions for people with depression?